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Abstract
Background: Idiopathic membranous nephropathy (IMN) is one of the most common forms of autoimmune
nephritic syndrome in adults. The purpose of this study is to evaluate whether polymorphisms of PLA2R1 affect the
development of IMN.
Methods: Taiwanese-Chinese individuals (129 patients with IMN and 106 healthy controls) were enrolled in this
study. The selected single nucleotide polymorphisms (SNPs) in PLA2R1 were genotyped by real-time polymerase
chain reaction using TaqMan fluorescent probes, and were further confirmed by polymerase chain reaction-
restriction fragment length polymorphism. The roles of the SNPs in disease progression were analyzed.
Results: Genotype distribution was significantly different between patients with IMN and controls for PLA2R1 SNP
rs35771982 (p = 0.015). The frequency of G allele at rs35771982 was significantly higher in patients with IMN as
compared with controls (p = 0.005). In addition, haplotypes of PLA2R1 may be used to predict the risk of IMN
(p = 0.004). Haplotype H1 plays a role in an increased risk of IMN while haplotype H3 plays a protective role
against this disease. None of these polymorphisms showed a significant and independent influence on the
progression of IMN and the risk of end-stage renal failure and death (ESRF/death). High disease progression in
patients having C/T genotype at rs6757188 and C/G genotype at rs35771982 were associated with a low rate of
remission.
Conclusions: Our results provide new evidence that genetic polymorphisms of PLA2R1 may be the underlying
cause of IMN, and the polymorphisms revealed by this study warrant further investigation.
Background
Podocytes are highly specialized cells that play a crucial
role in the glomerular filtration barrier [1,2]. Alterations
in surface molecules of podocytes lead to the accumula-
tion of antipodocytic antibodies on podocytes within the
kidney, which leads to autoimmune response and cell
damage [3]. When damage occurs, the interaction
between immune-related factors and damaged cells can
lead to foot process retraction, proteinuria, destruction
of the filtration barrier, nephritis, and subsequently
induction of end-stage renal failure and death (ESRF/
death) [4,5].
Accumulating evidence suggests that podocytes are the
primary target of injury in renal glomerular diseases [6-8].
Membranous nephropathy (MN) is one of the most com-
mon forms of nephrotic syndrome in adults, accounting
for 40% of cases of ESRF; it occurs after 10 years from the
time of the initial diagnosis of the disease [9]. One of its
subtypes, idiopathic MN (IMN), is an autoimmune disease
that represents approximately 75% of MN cases. This dis-
ease is characterized by thickening of the basement mem-
brane and subepithelial immune deposits without cellular
proliferation or infiltration [9]. Therapies for IMN that
include the use of immunosuppressive drugs and nonspe-
cific antiproteinuric measures have led to disappointing
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new therapeutic targets [10].
Phospholipase A2 receptor 1 (PLA2R1) belongs to the
mannose receptor family and is a type I transmembrane
glycoprotein (~180 kDa). It is composed of a large
extracellular portion that consists of an N-terminal
cysteine-rich region, a fibronectin-like type II domain,
a tandem repeat of 8 C-type lectin domains (CTLDs),
a transmembrane domain, and a short intracellular
C-terminal region [11,12]. PLA2R1 is known to regulate
a variety of biological responses that are elicited by
secretory phospholipase A2 (sPLA2) [11]. A recent
study identified antibodies specific to PLA2R1 in 70%
(26 of 37) of patients with IMN [13]. Although PLA2R1
has been proposed as the target autoantigen in IMN,
the relationship between the polymorphisms of PLA2R1
and the development of this disease has not yet been
examined. In this study, we analyzed the gene poly-
morphisms of PLA2R1 by using TaqMan allele discrimi-
nation, and examined their possible role in IMN.
Methods
Patients and controls
A disease group composed of 129 patients with biopsy-
diagnosed IMN and a gender-matched control group
composed of 106 healthy individuals, identified through
health examination at Taichung Veterans General
Hospital in Taiwan, were enrolled. All participants in
this study provided informed consent as approved by
the ethics committee of Taichung Veterans General
Hospital. Patients and controls are 85% Minnan descen-
dants; 5% Hakka descendants; and 10% mixed popula-
tion of Minnan, Hakka, and Canton descendants.
Patients
Patients with any evidence of secondary causes such as
malignancy, chronic infection with hepatitis B and C
viruses, lupus nephritis, or other specific diseases, were
excluded. The average age of patients was 59.8 (±17.4)
years for men and 53.7 (± 15.6) years for women; aver-
age body mass index (BMI) was 24.8 (± 3.6); 62 (48.1%)
patients were hypertensive, with blood pressure of >140/
90 mm Hg; 21 (16.3%) patients have ESRF requiring
renal replacement therapy; and 12 (9.3%) patients died
from IMN. The clinical data were collected from
patients at regular intervals as follows: the plasma crea-
tine was measured by UniCel DxC 800 PRO Synchron
clinical chemistry analyzer (Beckman Coulter Inc., Brea,
CA) using manufacturer’s reagents and the method is
standardized to the IDMS (isotope dilution mass spec-
trometry). Besides, the micro total protein assay (M-TP
assay, Beckman coulter) was used for the quantitative
determination of total urine protein. The M-TP reagent
was used to measure protein concerntration by a timed
endpoint method. Protein in the sample reacted with
the pyrogallol red (PR) molybdate (Mo) complex to
form a purple color that has a maximum absorbance at
6 0 0n m .T h ea s s a y sw e r em e a s u r e da tt h eT a i c h u n g
Veterans General Hospital, Taiwan. In addition, the pre-
sence of arterial hypertension with blood pressure >140/
90 mm Hg, and the presence of ESRF requiring renal
replacement therapy (Cockcroft was always below
15 mL/min) were recorded. All patients were treated
according to their needs: patients with hypertension
received optimal antihypertensive therapy, 113 (87.6%)
patients received angiotensin-converting enzyme inhibi-
tors (ACEIs) or angiotensin II receptor blockers (ARBs)
for heavy proteinurea, and 30 (23.3%) patients received
prednisolone. Some patients received more than 1 treat-
ment during the disease. The response and outcomes
were estimated by measuring the serum creatinine (Cr)
and the total urine protein as mentioned above. The
responses to therapy were defined as (1) no response;
(2) partial remission, defined as a proteinuria reduction
of >50% or a final proteinuria level between 0.2 and
2.0 g/day. (3) complete remission, defined as proteinuria
<0.2 g/day. Progression of renal disease was defined as a
doubling of baseline serum Cr values or ESRF. ESRF
was defined as an irreversible decline in kidney function
requiring renal replacement therapy. The inclusion
criteria are as follows: (1) individual must satisfy the
diagnostic criteria of IMN at the time of examination;
(2) individual is willing to participate and is capable of
giving informed consent; and (3) individual is a self-
reported non-aboriginal Taiwanese, and none of the par-
ents and grandparents has aboriginal background. The
exclusion criteria are as follows: (1) individual is unable
to understand or give informed consent or (2) individual
is pregnant or had childbirth within 1 year.
Controls
The control group was matched for gender (64 male
individuals [60.4%] and 42 female individuals [39.6%]) in
accordance with the predominance of IMN in men. The
average age was different in controls (27.3 ± 6.6 years)
compared with IMN patients (57.0 ± 16.9 years) (c
2 =
194.140, p =2 . 7 7 0×1 0
-15). The average BMI of con-
trols was 21.8 (± 3.1).
Single nucleotide polymorphism selection
The genotype information of PLA2R1 single nucleotide
polymorphism (SNP) was downloaded in December 2008
from the HapMap CHB + JPT population. HapMap
genotypes were analyzed with Haploview, and Tag SNPs
were selected using the Tagger function by applying the
following additional criteria: (1) a threshold minor allele
frequency in the HapMap CHB + JPT population of 0.05
for tag SNPs’ and (2) probe/primers that pass the qualifi-
cation as recommended by the manufacturer (Applied
Biosystems), to ensure a high genotyping success rate.
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(C/T) in intron 12, and a polymorphism that results in
amino acid change (His to Asp), SNP rs35771982 (C/G)
in exon 5 of the gene, were selected.
Genomic DNA extraction and genotyping
All samples from individuals were collected, by venipunc-
ture, for subsequent genomic DNA isolation. Genomic
DNA was extracted from peripheral blood leukocytes
using a genomic DNA kit (Qiagen) according to the
manufacturer’s instructions. Genotyping was achieved
using an assay-on-demand allelic discrimination assay
and detection system according to the manufacturer’s
instructions (Applied Biosystems). The reaction mixture
for the real-time polymerase chain reaction (PCR) con-
tained 10 ng of genomic DNA, 10 μL TaqMan master
mix, and 0.125 μL of 40× assay mix. PCR was performed
in 96-well plates on a thermal cycler (ABI 7700; Applied
Biosystems). Reaction conditions were 50°C for 2 min
and 95°C for 10 min, followed by 40 cycles at 95°C for
15 s and 60°C for 1 min. To confirm the quality and
accuracy of genotyping data from TaqMan assay, PCR-
restriction fragment length polymorphism (RFLP) was
performed. Amplification reaction was performed at the
total volume of 20 μL using a thermal cycler (ABI 9700;
Applied Biosystems). Reaction mixtures contained 100
ng genomic DNA, 10 pmol of each primer, 0.25 mmol of
dNTPs, 0.5 U ExTaq polymerase (Takara), and PCR
buffer.
rs6757188. The following primers were constructed:
forward primer 5’-AAAGGGCCCCGGAATAAAGGAA-3’
and reverse primer 5’-TTTCACCCCTG-CTATTTG-
GACTG-3’. The PCR product (149 bp) was digested
with the HpyCH4III restriction endonuclease enzyme
(New England Biolabs, NEB) at 37°C for 4 h followed by
3.5% agarose gel electrophoresis analysis. HpyCH4III
digestion of the PCR product yielded 49 bp and 100 bp
fragments for the C allele, whereas a single 149 bp frag-
ment was observed for the T allele (Fig. 1A).
rs35771982. The following primers were constructed:
forward primer 5’-GAAGCTCCATAATTTTCATTTCA-
GAGC-3’ and reverse primer 5’-GGCAAAGAAAA-
CACTGCGGGTA-3’.T h eP C Rp r o d u c t( 1 6 1b p )w a s
digested with the BbsI restriction endonuclease enzyme
(NEB) at 37°C for 4 h followed by 3.5% agarose gel elec-
trophoresis analysis. BbsI digestion of the PCR product
yielded 85 bp and 75 bp fragments for the G allele,
whereas a single 161 bp fragment was observed for the
C allele (Fig. 1B).
Statistical analysis
The allelic frequency and genotype frequency distribu-
tions of the polymorphisms in individuals with or with-
out IMN, or in IMN patients with several clinical
features, were analyzed by c
2 test, ANOVA test, or
Mantel-Haenszel test. The odds ratio (OR) was calcu-
lated from genotype and allelic frequencies with a 95%
confidence interval (95% CI). Haplotypes were inferred
from unphased genotype data using the Phase 2.1 pro-
gram based on the Bayesian algorithm [14]. Pairwise
linkage disequilibrium (LD) coefficients (r
2)b e t w e e n
SNPs were calculated to evaluate the structure of LD in
IMN patients and controls. The Kaplan-Meier method
was used to estimate cumulative survival, the results of
which were used to investigate the significant factors
influencing ESRF/death. SPSS Version 18.0 software was
used to analyze the data.
Results
PLA2R1 gene polymorphisms in IMN patients and in
controls
Two SNPs within PLA2R1 were genotyped in 129
patients with IMN and in 106 healthy controls. Analysis
of IMN patients in comparison with controls revealed a
significant difference in allelic distributions for the exon
5 SNP rs35771982 (p=0.005; ORallele G/allele C,1 . 9 0 0 ;
95% CI, 1.209-2.987). The significance remained after
applying the Bonferroni correction. The distribution of
SNP rs6757188 did not exhibit a significant association
Figure 1 Identification of phospholipase A2 receptor 1 (PLA2R1)
rs6757188 and rs35771982 genotypes by using polymerase
chain reaction-restriction fragment length polymorphism (PCR-
RFLP). (A) HpyCH4III restriction enzyme digestion of the intron
region at rs6757188. Lanes 1: DNA from an individual homozygous
for the polymorphic allele of T/T. Lane 2: DNA from an individual
homozygous for the polymorphic allele of C/T. Lane 3: DNA from an
individual heterozygous for the polymorphic allele of C/C. (B) BbsI
restriction enzyme digestion of the exon region at rs35771982. Lane
1: DNA from an individual homozygous for the polymorphic allele
of C/C. Lane 2: DNA from an individual homozygous for the
polymorphic allele of C/G. Lane 3: DNA from an individual
heterozygous for the polymorphic allele of G/G.
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for the genotype distributions (Table 1). These results
demonstrate that the G allele and the G/G genotype of
SNP rs35771982 may increase the incidence of IMN.
Haplotype analysis of PLA2R1
All the haplotypes presented in our study are shown in
Table 2. Comparisons of the haplotype frequencies
between patients with IMN and controls revealed signif-
icant differences (p = 0.004). Patients with IMN showed
an increase in frequency of haplotype H1 (OR = 1.647,
95% CI = 1.140-2.379). In addition, patients with IMN
also showed a decrease in frequencies of haplotype H3
(OR = 0.581, 95% CI = 0.368-0.919). These observations
suggest that H1 might increase the risk of development
of IMN, and H3 might decrease this risk.
The 235 individuals for whom PLA2R1 haplotypes were
evaluated were divided into 3 groups according to their
diplotypes (Table 2). The significance of haplotype H1
and H3 in diplotype analysis remained, although did not
meet the Bonferroni correction. For haplotype H1, there
were 52 homozygous haplotype H1 carriers (H1/H1), 118
heterozygous haplotype H1 carriers (H1/nonH1), and 69
individuals lacking haplotype H1 (nonH1/nonH1).
Patients with diplotype H1/H1, or with at least one H1
haplotype were associated with a 2.676-and 1.921-fold
greater susceptibility for IMN (p = 0.031 and 0.023, OR:
2.676 and 1.921, 95% CI 1.264-5.665 and 1.088-3.390,
respectively). In addition to H1, patients with at least one
haplotype H3 decreased the risk of development of IMN
by 54.4% (p = 0.025, OR: 0.544, 95% CI 0.318-0.930).
These results suggest that H1 may be a risk factor and
that H3 may inhibit the development of IMN.
LD analysis
To clarify the structure of the LD around rs6757188 and
rs35771982, r
2 values between the 2 SNPs were calcu-
lated. LD analysis for the rs6757188-rs35771982 region
revealed that the 2 polymorphisms, with or without
implication in IMN, were not in LD in both controls
and IMN patients (all r
2 < 0.030).
Relationship between rs6757188 and rs35771982
polymorphisms and clinical features of IMN
The role of the risk PLA2R1 polymorphisms in the pro-
gression of disease toward ESRF/death was investigated.
Non of the risk allele, the risk haplotype nor the protec-
tive haplotype of PLA2R1 had an effect on survival with-
out ESRF/death (Fig. 2). Clinical features of IMN patients
with genotypes of the 2 PLA2R1 polymorphisms are
shown (Additional file 1: Table S1). No significant differ-
ence was found in gender distribution, age, BMI, systolic
blood pressure, diastolic blood pressure, serum albumin
level, haematuia or proteinuria. The initial laboratory test
reveals no difference in baseline serum Cr level, daily
urinary protein excretion (DUP), or creatinine clearance
(CCr). After a mean of 6.3 ± 5.1 years follow-up, there
was no significant difference in the last measured serum
Cr level, last measured urine protein level, or last mea-
sured CCr level. In the 104 of 129 cases (80.6%) with
clinical-pathological records of biopsies results, the
grades of IMN patients were not significantly different
among the genotypes of the 2 polymorphisms.
Relationship between gene polymorphisms and
treatment outcomes
Outcomes of IMN patients treated with either suppor-
tive or aggressive immunosuppressants were not differ-
ent among the different genotype groups of rs6757188
and rs35771982 polymorphisms. Mantel-Haenszel test
revealed that the genotype C/T at rs6757188 and the
genotype with C/G at rs35771982 were associated with
a low rate of remission during disease progression after
therapy (Additional file 2: Table S2).
Table 1 Genotype and allele frequencies of phospholipase
A2 receptor 1 (PLA2R1) single nucleotide polymorphisms
(SNPs) in patients with idiopathic membranous
nephropathy (IMN) vs healthy controls
SNPs Controls
N (%)
IMN
N (%)
p-Value
a Odds ratio (95% CI)
b
Alleles
rs6757188
C allele 76 (35.8) 83 (32.3) 0.402 1
T allele 136 (64.2) 175 (67.8) 1.178 (0.803–1.729)
Total 212 (100) 258 (100)
rs35771982
C allele 56 (26.4) 41 (15.9) 0.005 1
G allele 156 (73.6) 217 (84.1) 1.900 (1.209–2.987)
Total 212 (100) 258 (100)
Genotypes
rs6757188
C/C 9 (8.5) 15 (11.6) 0.113 1
C/T 58 (54.7) 53 (41.1) 0.548 (0.221–1.357)
T/T 39 (36.8) 61 (47.3) 0.938 (0.374–2.352)
Total 106 (100) 129 (100)
rs35771982
C/C 8 (7.5) 2 (1.6) 0.015 1
C/G 40 (37.7) 37 (28.7) 3.700 (0.738–18.560)
G/G 58 (54.7) 90 (69.7) 6.207 (1.273–30.262)
Total 106 (100) 129 (100)
Abbreviation: CI, confidence interval.
a Genotype frequencies were determined by c
2 test using 2 × 3 contingency
tables between patients with IMN and healthy controls. Allele frequencies and
restricted genotypes were determined by c
2 test using 2 × 2 contingency
tables between patients with IMN and healthy controls.
b Odds ratios and 95% CI per genotype and allele were estimated by applying
unconditional logistic regression between patients with IMN and healthy
controls.
Liu et al. Journal of Biomedical Science 2010, 17:81
http://www.jbiomedsci.com/content/17/1/81
Page 4 of 8The risk PLA2R1 polymorphisms did not associated with
ESRF/death
T h er o l eo ft h er i s kPLA2R1 polymorphisms in the dis-
ease progression toward ESRF/death was investigated.
None of the risk allele, risk haplotype nor protective
haplotype of PLA2R1 had an effect on survival without
ESRF/death (Fig. 2).
Discussion
The polymorphisms of several candidate genes, such as
plasminogen activator inhibitor-1 (PAI-1) [15], tumor
necrosis factor A (TNFA)[ 1 6 ] ,metallomembrane endo-
peptidase (MME) [17], major histocompatibility complex
(MHC) class II [18], and complement factor B subtype
FA (FB*FA) [19], have been reported to contribute to
IMN. Although PLA2R1 has been proposed to represent
the target autoantigen for IMN [13], the occurrence of
PLA2R1polymorphisms in IMN patients has not been
investigated. In this study, we investigated 2 SNPs
(rs6757188 and rs35771982) in PLA2R1 and their asso-
ciation with IMN. Our results suggest that the G allele
at SNP rs35771982 in exon 5 may increase this risk of
this disease. Although the disease-associated PLA2R1
haplotype may not be limited to the SNPs we have ana-
lyzed, our data demonstrate that the haplotype H1-TG
may represent a susceptibility haplotype for IMN, while
H3-TC may be a protective haplotype. To our knowl-
edge, this is the first study to demonstrate that PLA2R1
polymorphisms may be associated with the development
of IMN. These findings suggest that PLA2R1 may play a
pathogenic role in inducing or maintaining glomerular
barrier dysfunction in humans.
The role of PLA2R1 in the pathogenesis of IMN is sup-
ported by evidence of high urinary levels of this
Table 2 Haplotypes according to the presence of phospholipase A2 receptor 1 (PLA2R1) single nucleotide
polymorphisms (SNPs) in patients with idiopathic membranous nephropathy (IMN) vs healthy controls
Polymorphisms Controls
N (%)
IMN
N (%)
p-Value Odds ratio (95% CI)
e
Haplotype
a
H1-TG 84 (39.6) 134 (51.9) 0.004
b 1.647 (1.140–2.379)
H2-CG 72 (34.0) 83 (32.2) 0.922 (0.627–1.357)
H3-TC 52 (24.5) 41 (15.9) 0.581 (0.368–0.919)
H4-CC 4 (1.9) 0 (0.0) 0.005 (0.000–)
Diplotypes
a
H1/H1 + H1/nonH1 67 (63.2) 99 (76.7) 0.023
c 1.921 (1.088–3.390)
H1/H1 17 (16.0) 35 (27.1) 0.031
d 2.676 (1.264–5.665)
H1/nonH1 54 (47.2) 64 (49.6) 1.664 (0.911–3.041)
nonH1/nonH1 39 (36.8) 30 (23.3) 1
H2/H2 + H2/nonH2 64 (60.4) 68 (52.7) 0.239
c 1.921 (1.088–3.390)
H2/H2 8 (7.5) 15 (11.6) 0.174
d 2.676 (1.264–5.665)
H2/nonH2 56 (52.8) 53 (41.1) 1.664 (0.911–3.041)
nonH2/nonH2 42 (39.6) 61 (47.3) 1
H3/H3 + H3/nonH3 47 (44.3) 39 (30.2) 0.025
c 0.544 (0.318–0.930)
H3/H3 5 (4.7) 2 (1.6) 0.053
d 0.262 (0.049–1.396)
H3/nonH3 42 (39.6) 37 (28.7) 0.578 (0.333–1.002)
nonH3/nonH3 59 (55.7) 90 (69.8) 1
H4/H4 + H4/nonH4 4 (3.8) 0 (0.0) 0.026
c 0.000 (0.000–)
H4/H4 0 (0.0) 0 (0.0) 0.026
d –
H4/nonH4 4 (3.8) 0 (0.0) 0.000 (0.000–)
nonH4/nonH4 102 (96.2) 129 (100.0) 1
Abbreviations: CI, confidence interval; H, haplotype.
a Order of SNPs comprising the PLA2R1 haplotypes: rs6757188, and rs35771982. The haplotypes were identified by the Baysian statistical method available in the
program Phase 2.1.
b The significance of haplotype frequency for IMN development was determined by chi-square test using 4 × 2 contingency tables.
c Individual haplotype frequencies for IMN development were determined by chi-square test using 2 × 2 contingency tables.
d The significance of diplotype frequency for IMN development were determined by chi-square test using 3 × 2 contingency tables.
e Odds ratios and 95% CI per haplotype or diplotype were estimated by applying unconditional logistic regression between patients with IMN and healthy controls.
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PLA2R1 antibodies in patients with IMN [13]. To date,
however, its role in the development of IMN has not been
elucidated. The PLA2R1 gene is located on chromosome
2q23-q24 [12]. Polymorphisms in PLA2R1 m a yh a v ea
direct effect on the gene function, but this has rarely been
discussed. PLA2R1 is naturally expressed on the cell mem-
brane of podocytes and acts as a receptor for sPLA2. This
receptor participates in both positive and negative regula-
tion of sPLA2, which is involved in the induction of cell
proliferation, cell adhesion, production of lipid mediators,
and release of arachidonic acid [11]. Our findings demon-
strate that the G allele of SNP rs35771982 in exon 5,
which results in a residue change (H300D) in the second
of the 8 CTLDs, appears to be more selectively expressed
in IMN patients than in controls. CTLDs are involved in
several functions, such as extracellular matrix organiza-
tion, endocytosis, complement activation, pathogen recog-
nition, and cell-cell interactions [11,20,21]. Alterations in
the structures of these domains may affect these important
functions. Overproduction of serum PLA2R1 antibodies
that has been observed in individuals may be linked to the
A/G allele of SNP rs35771982. Although the intron 12
SNP rs6757188 of PLA2R1 was not statistically linked to
the development of IMN, the T allele of rs6757188 has a
protective effect on the development of global sclerosis
and tubulointerstitial fibrosis (data not shown). Confirma-
tion of these results in larger samples is warranted.
One aim of genetic studies is to provide information
about the prognosis of a given disease. IMN exhibits
large interindividual variations in the progression toward
ESRF/death. Aggressive therapies with steroids and
immunosuppressive drugs such as Ponticelli’sp r o t o c o l
[22] or cyclosporine [23] cause many side effects [9].
Therefore, it is important to identify markers for the
early identification of patients who are at risk for the
progression of this disease. Indeed, several factors have
been identified for predicting poor prognosis [24,25].
However, our investigation of the association between
PLA2R1 polymorphisms and ESRF/death did not pro-
vide genetic information for predicting the risk of ESRF/
death.
In addition, a correlation has emerged between plasmi-
nogen activator inhibitor-1 4G allele and IMN progres-
sion. Stratified analysis using the Mantel-Haenszel
statistic revealed a high disease progression in 4G4G gen-
otype patients with no remission of proteinuria [15].
Moreover, the A/A genotype for rs401824 and the G/G
genotype for rs437168 of the NPHS1 gene show correla-
tion with no remission of proteinuria [26]. Similarly, we
observed disease progression in the C/T genotype for
rs6757188, and the C/G genotype for rs35771982 showed
correlation with a low rate of remission of proteinuria.
Most of the patients in this study were treated with
ACEIs and ARBs. Despite the similar mode of treatment
given to our patients, more disease progression was
found in patients with C/T genotype of rs6757188 as well
as C/G genotype of rs35771982 than in other subgroups,
suggesting that more specific drugs targeting biosynthesis
or activity of PLA2R1 may supplement regular immuno-
suppressive regimens, particularly in patients with C/T
genotype of rs6757188 and C/G genotype of rs35771982.
Conclusions
This study provides evidence that genetic factors are
responsible for the development and progression of
Figure 2 Risk polymorphism, risk haplotype and protective haplotype of phospholipase A2 receptor 1 (PLA2R1) and survival without
end-stage renal failure (ESRF)/death. (A) Survival without ESRF/death of individuals with or without the risk G allele at rs35771982 of PLA2R1
(log rank significance: 0.74). (B) Survival without ESRF/death of individuals with or without the risk haplotype 1 of PLA2R1 (log rank significance:
0.77). (C) Survival without ESRF/death of individuals with or without the protective haplotype 3 of PLA2R1 (log rank significance: 0.70).
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the PLA2R1 SNP rs35771982 and the H1-TG haplotype
may initiate, while the H3-TC m a yd e c r e a s et h er i s ko f
IMN. In addition, the presence of C/T genotype of
rs6757188 and C/G genotype of rs35771982 leads to a
low rate of remission during IMN progression after
therapy. This study provides evidence that SNPs in the
PLA2R1 gene are associated with the risk of develop-
ment and progression of IMN. These results might aid
diagnosis during the early stage of disease and may be
valuable for therapeutic studies in the Taiwanese
population.
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genotype with C/G at rs35771982 were associated with a low rate of
remission during disease progression after therapy.
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